Bolt Biotherapeutics Inc BOLT

Healthcare Biotechnology

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A...

NDAQ:BOLT - Post by User

Bolt Biotherapeutics Inc

Bullboard Posts

Next >>

(10)
•••

Post by MikeTesteron Aug 03, 2024 4:17pm

81 Views

Post# 36163458

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT): Pivoting to a Focu

https://beyondspx.com/2024/08/02/bolt-biotherapeutics-inc-nasdaqbolt-pivoting-to-a-focused-pipeline-and-streamlined-operations-to-maximize-shareholder-value/

Bullboard Posts

Next >>

Mink Ventures defines eight new high-priority drill targets